BioNTech SE (BNTX) Share-based Compensation (IS) (2020 - 2025)

BioNTech SE has disclosed Share-based Compensation (IS) across 6 years of filings, most recently posting -$7.0 million for Q4 2025.

• Share-based Compensation (IS) for Q4 2025 came in at -$7.0 million, up 40.04% year-over-year; the trailing twelve-month figure through Dec 2025 was -$28.7 million (up 83.04% YoY), and the FY2025 annual result was -$28.6 million, up 82.69% from the prior year.
• Share-based Compensation (IS) came in at -$7.0 million for Q4 2025 at BioNTech SE, down from -$4.9 million in the prior quarter.
• In the past five years, Share-based Compensation (IS) ranged from a high of $5.4 million in Q1 2021 to a low of -$778.9 million in Q1 2023.
• The 5-year median for Share-based Compensation (IS) is -$5.1 million (2023), against an average of -$59.6 million.
• Across the five-year window, Share-based Compensation (IS) slumped 38456.63% in 2023 and soared 99.67% in 2024, its largest moves.
• BioNTech SE's Share-based Compensation (IS) stood at -$2.7 million in 2021, then sank by 1650.25% to -$48.1 million in 2022, then jumped by 88.8% to -$5.4 million in 2023, then sank by 116.51% to -$11.6 million in 2024, then surged by 40.04% to -$7.0 million in 2025.
• The last three Share-based Compensation (IS) figures came in at -$7.0 million (Q4 2025), -$4.9 million (Q3 2025), and -$13.0 million (Q2 2025), per Business Quant data.